Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Radiopharm Theranostics on Sharewise webinar

Wednesday, November 27, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has successfully dosed its first patient in a Phase 1/2a clinical study of BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate this therapeutic study targeting B7H3. Additionally, Radiopharm has shared positive updates regarding four of its clinical programs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has initiated a Phase 1/2a clinical study.
  • The company has received IND approval from the US FDA.
  • Positive clinical updates were provided across four programs.

Full Press Release Details

• Updates
• Video
• November 27, 2024

More Announcements & Updates

• Announcements
• December 9, 2022
• Announcements
• January 6, 2023
• Announcements
• September 28, 2023
• Announcements
• July 17, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the focus of Radiopharm's clinical study?

The clinical study focuses on BetaBart (RV-01) targeting B7H3.

When did Radiopharm dose its first patient?

Radiopharm dosed its first patient in the Phase 1/2a study recently.

What approval did Radiopharm receive from the FDA?

Radiopharm received IND approval to initiate its therapeutic clinical study.

How many programs received positive updates?

Radiopharm provided positive updates across four clinical programs.

Tags: RADX Viatris Investor Conferences Healthcare BetaBart Phase 1/2a clinical study FDA approval
Last updated: Nov 27, 2024